Cencora's shares are down due to the loss of a significant portion of Walgreens' business, effective July 2026. This long-term revenue hit creates uncertainty for Cencora's future earnings and market share, while potentially benefiting competitors.
This news is a significant corporate catalyst for Cencora (COR) as it signals a future reduction in revenue and market share due to the loss of a portion of Walgreens' business. While the impact isn't immediate (July 2026), the market is pricing in this future uncertainty, leading to a negative reaction in Cencora's stock. The pharmaceutical distribution sector is highly competitive, and such a large customer shift could benefit Cencora's rivals like Cardinal Health (CAH) and McKesson (MCK), who might absorb the redirected Walgreens volume. Traders should monitor Cencora for continued downside pressure and consider potential upside for its competitors as they vie for the new business.